Unlocking NATURE potential
Harnessing AI and nature to redefine the pace of drug discovery, uncovering bioactive compounds with unprecedented precision and speed.
Our Story / Our Technology / Impact / Our Partners /
Our Story / Our Technology / Impact / Our Partners /
Our Story / Our Technology / Impact / Our Partners
Our Story
Nature has always been humanity’s greatest teacher, and for us, it is deeply woven into our history, culture, and daily life. For centuries, the healing power of plants has been a cornerstone of wellness across generations in Asia.
At NYB, we honor this legacy by uniting centuries of cultural wisdom with groundbreaking innovation. Leveraging state-of-the-art AI technologies and scientific expertise, we uncover nature’s hidden treasures—bioactive compounds that hold the potential to transform billions of lives.
At NYB, we honor this legacy by uniting centuries of cultural wisdom with groundbreaking innovation. Leveraging state-of-the-art AI technologies and scientific expertise, we uncover nature’s hidden treasures—bioactive compounds that hold the potential to transform billions of lives.
Our Techonology
Building on this heritage, we developed DTIGN—our proprietary Drug-Target Interaction Graph Neural Network. DTIGN represents the future of drug discovery by simulating molecular interactions at the atomic level, enabling unparalleled identification of bioactive compounds with transformative potential.
Our Techonology
By blending nature’s insights with advanced technology, we accelerate the discovery of compounds that power the next generation of health and wellness products.
Impact
2B+
compound library
64x
higher hit rates than the most popular docking software
10M+
natural compounds
44.83%
increase in bioactivity prediction efficiency
Our Partner
To us, partnership means possibility. We work closely with visionary organizations to uncover groundbreaking solutions from nature’s untapped potential. By integrating our advanced AI capabilities with the expertise and goals of our partners, we accelerate bioactive compound discovery beyond industry standards.
Press & media
.jpg)
Press
[Computer Weekly] Pharma leaders see AI revolutionising medicine
NYB AI is featured in Computer Weekly’s coverage of Gitex Asia 2025, where industry leaders discussed how AI is revolutionizing drug discovery and development.
Press
[Tech in Asia] Transforming drug discovery in Southeast Asia via AI
NYB AI is featured in Tech in Asia for pioneering AI-driven drug discovery in Southeast Asia.
Press
[The Business Times] Revolutionising drug discovery with AI in South-east Asia
NYB AI is featured in The Business Times for transforming drug discovery in Southeast Asia with its AI platform, DTIGN.
Featured news
Company
Nanyang Biologics Showcases AI Drug Discovery at COMPUTEX 2025
Nanyang Biologics (NYB) made a strong presence at COMPUTEX 2025, one of the world's premier technology exhibitions, held from May 20–23 at the Taipei Nangang Exhibition Center. The event, themed "AI Next," brought together global leaders in artificial intelligence, robotics, and next-generation technologies who are driving the future of innovation.
Partnership
Nanyang Biologics and Precisya Global Form Strategic Alliance to Leverage AI in Validating Natural Compounds for Genetic Risk Mitigation
Nanyang Biologics (NYB) and Precisya Global Inc. (PGI) have partnered to combine AI-powered compound discovery with advanced genetic risk profiling - bringing a new dimension to precision health through nature-derived interventions.
Company
Nanyang Biologics at GITEX ASIA SINGAPORE 2025
Nanyang Biologics will be joining GITEX ASIA – Asia’s largest and most global tech, startup, and digital investment event – taking place from April 23 to 25 at Marina Bay Sands, Singapore.
